The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149.
Maria Creselda deLeon
No relevant relationships to disclose
Alesha Arnold
No relevant relationships to disclose
Emma Caroline Rossi
No relevant relationships to disclose
Jamie Case
No relevant relationships to disclose
Cynthia Johnson
No relevant relationships to disclose
Yan Zeng
No relevant relationships to disclose
Daniela Matei
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim